ERBB2 and breast carcinoma: That panel did however recognise the potential prohibitive cost of wide-spread multigene expression analysis, and instead propositioned immunohistochemical surrogates such as dichotomising ERα positive breast cancer cases on the basis of PR and Ki67 positivity thresholds and HER2 status, even though such measures have been found to be less accurate [17, 60, 65].